CF Industries
CF
$123.24
+0.72%
CF Industries is a leading global producer and distributor of nitrogen-based fertilizers, operating nitrogen manufacturing complexes primarily in North America alongside assets in the United Kingdom and a joint venture in Trinidad and Tobago, serving the agricultural inputs industry. The company's structural advantage is its access to low-cost US natural gas feedstock, which positions it among the lowest-cost nitrogen producers globally and gives it a durable cost-curve moat versus European and Asian competitors reliant on costlier inputs. The current investor narrative centers on the extraordinary margin windfall created by the Strait of Hormuz disruption, which stranded roughly a third of global fertilizer supply and drove CF's quarterly gross margins from the mid-30s into the low-50s at the Q2 2026 peak, while the company simultaneously markets a longer-dated blue and green ammonia growth story tied to clean energy and hydrogen transport. Debate now hinges on the durability of these elevated nitrogen prices as geopolitical risk premiums unwind, with shares up roughly 47% over the past year but having stalled since September as the market weighs normalized earnings power against a still-attractive 2.6% dividend yield and aggressive buyback program.…
CF
CF Industries
$123.24
Investment Opinion: Should I buy CF Today?
Rating: Hold. CF is a genuinely cheap, low-beta, cash-gushing nitrogen producer (8.61x trailing PE, 4.41x EV/EBITDA, $2.08 billion TTM free cash flow) whose earnings are inflated by a now-unwinding Hormuz supply shock, and the 13-Hold/6-Buy/3-Sell consensus with a $128.79 average target (only 7.9% upside from $119.39) frames the stock as fairly valued rather than compelling at this price. The core thesis is that the low-cost US gas moat and ~10% share-count reduction (168.8 million to 151.6 million diluted shares) protect per-share value even as the margin windfall fades, but the market is right to demand a discount until normalized nitrogen pricing is proven.
Supporting evidence cuts both ways. On the positive side, Q3 2026 revenue of $1.86 billion grew 12.12% year-over-year, gross margin of 38.71% still exceeded the 38.1% Q3 2025 baseline despite a 12.8-point sequential collapse from the 51.53% Q2 peak, trailing operating margin of 33.39% and ROE of 30.07% are roughly double typical agricultural input peers, and the 2.6% dividend yield is covered by a conservative 22.4% payout ratio. Against that, the forward PE of 10.64x sits above the trailing 8.61x — an inversion signaling expected earnings decline — and the 86% spread between the $105 low and $195.72 high analyst targets quantifies how little agreement exists on mid-cycle earnings power.
Three risks could invalidate the thesis: nitrogen prices normalizing toward pre-shock levels (Q3 EPS already fell to $2.88 from $4.74), the geopolitical premium fully unwinding after the April 2026 Hormuz reopening, and interest expense spiking to $168 million in Q3 from $50 million in Q2. This Hold would upgrade to Buy if the stock pulls back toward the $105-$111 support zone (implying ~7.5x forward EPS) or if Q4 gross margin holds above 38% with consensus EPS revisions stabilizing near $8.795; it would downgrade to Sell on a decisive break below $111 or evidence that forward EPS is tracking toward the $7.86 low estimate. Net verdict: fairly valued to modestly undervalued versus its own 10.0x-11.3x 2024-2025 PE history, but the discount to the 12x-18x peer range is largely deserved given cyclical earnings risk.
Sign up to view all
CF 12-Month Price Forecast
CF presents a fairly valued cyclical at an inflection point: the 8.61x trailing and 4.41x EV/EBITDA multiples look cheap against 12x-18x peers, but the forward-over-trailing PE inversion correctly prices in earnings normalization after the Hormuz windfall. The low 0.541 beta and 36.99-point one-year relative strength versus SPY make it an attractive low-volatility cyclical, and the buyback plus dividend provide a floor, but the 86% analyst target spread ($105 to $195.72) shows genuine disagreement about mid-cycle earnings. With the stock at 65.8% of its 52-week range and momentum stalled since September, the risk/reward is balanced rather than asymmetric. I would upgrade to bullish if Q4 gross margin holds above 38% and EPS revisions stabilize near $8.795, or if the stock pulls back toward $105-$111; I would downgrade to bearish on a break below $111 or forward EPS tracking toward the $7.86 low.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on CF Industries's 12-month outlook, with a consensus price target around $129.44 and implied upside of +5.0% versus the current price.
Average Target
$129.44
22 analysts
Implied Upside
+5.0%
vs. current price
Analyst Count
22
covering this stock
Price Range
$105 - $196
Analyst target range
Coverage is broad with 20 analysts, but sentiment is decidedly cautious: 6 Buy, 13 Hold, and 3 Sell ratings produce a consensus recommendation of "hold" and a recommendation mean of 2.82 (where 3.0 is a pure hold). The average target price of $128.79 implies roughly 7.9% upside from the current $119.39, a modest expected return that aligns with the neutral consensus and suggests the Street views the stock as fairly valued after its 47% run. The heavy Hold skew reflects genuine disagreement about normalized nitrogen pricing rather than lack of interest, and the consensus EPS estimate of $8.795 (range $7.86 to $11.99) versus estimated revenue of $6.91 billion frames the debate around how much of the 2026 windfall persists.
The target range is extraordinarily wide — from $105 to $195.72, a spread of over 86% relative to the low end — signaling high uncertainty about the durability of the margin cycle. The $195.72 high target implies roughly 64% upside and would require either sustained elevated nitrogen prices, multiple expansion toward peer levels, or successful execution on the blue/green ammonia growth optionality; the $105 low target implies about 12% downside and prices in a full normalization of fertilizer prices toward pre-shock levels with margin compression. Institutional rating flow is mixed but marginally constructive: Rothschild & Co upgraded from Sell to Neutral in September 2026 and Scotiabank moved from Sector Perform to Sector Outperform in June 2026, while UBS, CIBC, Morgan Stanley, and JP Morgan all maintained Neutral/Equal Weight stances through October — a pattern of cautious stabilization rather than conviction buying, consistent with a stock whose near-term upside is capped by cyclical uncertainty despite an undeniably cheap multiple.
Bulls vs Bears: CF Investment Factors
The bull case rests on a genuinely cheap valuation (8.61x trailing PE, 4.41x EV/EBITDA), a durable low-cost gas advantage, and $2.08 billion of TTM free cash flow funding a ~10% share-count reduction, all achieved with a low 0.541 beta. The bear case rests on the fact that current earnings are inflated by a now-unwinding geopolitical shock, evidenced by the forward PE exceeding the trailing PE and Q3 gross margin compressing 12.8 points sequentially from the Q2 peak. On balance the bear evidence currently carries slightly more weight for near-term direction, because the Hormuz reopening and cautious 13-Hold consensus cap upside to the modest 7.9% implied by the $128.79 average target. The single most important tension is whether baseline nitrogen pricing has structurally reset higher or reverts toward pre-shock levels — if mid-cycle earnings hold near the $8.795 consensus EPS, the 10.64x forward multiple is too cheap and the stock re-rates; if they roll back toward 2025 levels, the discount is deserved.
Bullish
- Deep discount to sector multiples: CF trades at 8.61x trailing and 10.64x forward earnings versus the 12x-18x range typical for agricultural chemical peers, a 30-50% discount. EV/EBITDA of just 4.41x on a business generating 54.8% EBITDA margins leaves substantial room for multiple expansion if mid-cycle earnings confidence improves.
- Low-cost gas moat sustains margins: Access to cheap US natural gas keeps CF among the lowest-cost nitrogen producers globally, evidenced by a 33.39% trailing operating margin and 30.07% ROE that are roughly double typical agricultural input peers. Even after Q3 normalization, gross margin of 38.71% held above the 38.1% Q3 2025 baseline.
- Powerful cash generation and buybacks: TTM free cash flow of $2.081 billion funded $282 million of quarterly capex, $91 million of dividends, and $357 million of buybacks in Q3 2026 entirely from internal cash, lifting cash to $2.82 billion. Diluted shares fell from 168.8 million in Q1 2025 to 151.6 million in Q3 2026, a ~10% reduction that amplifies per-share value.
- Revenue still growing double digits: Q3 2026 revenue of $1.86 billion grew 12.12% year-over-year against $1.659 billion in Q3 2025, with UAN ($639 million) and Ammonia ($534 million) as the largest contributors. The year-over-year comparison remains strongly positive even as the acute Hormuz price spike fades sequentially from the $2.222 billion Q2 peak.
Bearish
- Earnings windfall is mean-reverting: The forward PE of 10.64x sits above the trailing 8.61x, an inversion that signals the market expects the Hormuz-driven earnings spike to fade. Consensus forward EPS of $8.795 implies roughly $1.33 billion of net income versus the trailing run-rate, and Q3 gross margin already compressed from 51.53% to 38.71% sequentially.
- Analyst consensus is only a hold: Of 20 analysts, 13 rate Hold versus just 6 Buy and 3 Sell, producing a recommendation mean of 2.82 and an average target of $128.79 that implies only 7.9% upside from $119.39. The $105 low target implies ~12% downside and prices in full normalization of fertilizer prices.
- Geopolitical premium is unwinding: News flow shows the Strait of Hormuz reopened in April 2026 with crude plunging 14% and oil sinking 5% on Iran truce hopes in May, directly removing the supply disruption that stranded a third of global fertilizer supply. As that risk premium unwinds, nitrogen prices and CF's margin windfall face continued normalization pressure.
- Momentum has stalled since September: Despite a 48.99% YTD gain, the stock has churned sideways, up only 4.33% over one month and 4.41% over three months, and sits at 65.8% of its 52-week range after a 25.75% max drawdown from the $141.96 peak. The September high near $139 has not been reclaimed, capping near-term upside.
CF Technical Analysis
CF is in a sustained but maturing uptrend, with the stock up 46.58% over the past year and 48.99% year-to-date, dramatically outperforming the S&P 500's 9.59% and 7.83% respective gains. At the current price of $119.39, the stock sits at roughly 65.8% of its 52-week range of $75.42 to $141.96, meaning it has surrendered a meaningful portion of its highs but remains far above the lows — a positioning consistent with a momentum leader digesting gains rather than a broken trend. The 25.75% max drawdown figure confirms the stock has already endured a sharp correction from its peak, so the current level represents a mid-range consolidation zone rather than an overextended or deeply discounted entry point.
Short-term momentum is modestly positive but decelerating relative to the annual trend: the stock is up 4.33% over one month and 4.41% over three months, a fraction of the 46.58% one-year advance, signaling that the powerful 2026 rally has flattened into a sideways churn. Critically, this flat absolute performance masks strong relative strength — CF has outperformed SPY by 9.32 percentage points over one month and 9.32 points over three months while the index fell 4.99% and 4.91% respectively, and relative strength over the trailing year stands at a remarkable 36.99 points. The recent price action shows a September peak near $139 followed by a pullback to the $111-$115 zone in late September and early October, then a recovery to the $118-$123 range, with the November 4 dip to $111.68 quickly bought back to $119.39 — a constructive higher-low pattern that suggests buyers are defending the low-$110s.
Key technical support rests at the 52-week low of $75.42, with a more actionable near-term floor at the $111-$115 congestion zone that has held on multiple tests in October and November; resistance sits at the 52-week high of $141.96, with intermediate supply around the $135-$139 September highs. A breakout above $142 would confirm resumption of the primary uptrend and likely trigger momentum-chasing flows, while a breakdown below $111 would break the recent higher-low structure and open a path toward the $100 psychological level. The stock's beta of just 0.541 is a critical risk-management input — CF is roughly 46% less volatile than the broader market, meaning its 46.58% one-year gain was achieved with unusually low systematic risk, making it an attractive low-beta cyclical and implying that position sizing can be larger for equivalent portfolio risk contribution.
Beta
0.54
0.54x market volatility
Max Drawdown
-25.8%
Largest decline past year
52-Week Range
$75-$142
Price range past year
Annual Return
+47.3%
Cumulative gain past year
| Period | CF Return | S&P 500 |
|---|---|---|
| 1m | +7.6% | -2.4% |
| 3m | +5.3% | -2.3% |
| 6m | -1.6% | +2.8% |
| 1y | +47.3% | +11.3% |
| ytd | +53.8% | +11.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CF Fundamental Analysis
CF's revenue trajectory is re-accelerating sharply: Q3 2026 revenue of $1.86 billion grew 12.12% year-over-year against $1.659 billion in Q3 2025, and the multi-quarter arc shows a clear upward inflection from $1.663 billion in Q1 2025 through $1.89 billion, $1.659 billion, $1.872 billion, $1.986 billion, a peak of $2.222 billion in Q2 2026, and $1.86 billion in Q3 2026. The sequential decline from the Q2 peak reflects the fading of the acute Hormuz-driven price spike, but the year-over-year comparison remains strongly positive, and segment data shows UAN at $639 million and Ammonia at $534 million as the largest contributors, with Urea at $456 million and AN at just $67 million. The growth trend implies the investment case is transitioning from a geopolitical windfall story to a test of whether baseline nitrogen pricing has structurally reset higher — a question the Q3 sequential softening leaves genuinely open.
Profitability is exceptional for a commodity chemical producer: Q3 2026 net income of $436 million on a 23.44% net margin and 38.71% gross margin, with operating income of $701 million (37.69% operating margin) and EBITDA of $1.02 billion (54.84% EBITDA margin). Margins have compressed from the Q2 2026 peak — gross margin fell from 51.53% to 38.71% and net margin from 32.72% to 23.44% — but remain well above the 2025 baseline of roughly 38.1% gross margin in Q3 2025 and far above the 34.4% gross margin recorded in Q1 2025. The compression is a normalization from an unsustainable spike rather than fundamental deterioration, and the 33.39% trailing operating margin and 20.54% net margin remain roughly double what is typical for agricultural input producers, underscoring the durability of CF's low-cost gas advantage even as spot nitrogen prices cool.
Financial health is robust: debt-to-equity of 0.816 is moderate for a capital-intensive manufacturer, the current ratio of 3.37 signals ample liquidity, and ROE of 30.07% and ROA of 12.61% are outstanding. Free cash flow is powerful — $2.081 billion TTM, with quarterly FCF of $888 million in Q3 2026, $607 million in Q2, and $273 million in Q1 — funding $282 million of quarterly capex, $91 million of dividends, and $357 million of buybacks in Q3 alone, all from internally generated cash with cash balances rising to $2.82 billion. The 4.56x price-to-cash-flow ratio and 22.4% payout ratio confirm the company is self-funding growth and returning substantial capital, with the buyback shrinking diluted shares from 168.8 million in Q1 2025 to 151.6 million in Q3 2026 — a roughly 10% reduction that materially amplifies per-share value creation.
Quarterly Revenue
$1.9B
2026-09
Revenue YoY Growth
+12.1%
YoY Comparison
Gross Margin
38.7%
Latest Quarter
Free Cash Flow
$2.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CF Overvalued?
Because CF is solidly profitable with trailing net income well above zero, the PE ratio is the appropriate primary metric. The stock trades at just 8.61x trailing earnings and 10.64x forward earnings — the forward multiple sitting above the trailing figure is unusual and reflects the market's expectation that the Hormuz-driven earnings spike will mean-revert, with consensus forward EPS of $8.795 implying roughly $1.33 billion of net income versus the trailing run-rate that produced the 8.6x multiple. The 0.26 PEG ratio and 1.77x PS ratio suggest the market is pricing CF as a cheap, low-growth cyclical rather than a structural compounder.
Against a sector where agricultural chemical peers typically trade in the 12x-18x PE range, CF's 8.61x trailing and 10.64x forward multiples represent a meaningful discount of roughly 30-50%, and its 2.70x EV/Sales and 4.41x EV/EBITDA are similarly modest for a business generating 54.8% EBITDA margins and 30.1% ROE. The discount is partly justified — nitrogen pricing is cyclical and the current earnings base is inflated by a geopolitical shock — but the 2.59x price-to-book and 2.6% dividend yield provide valuation support, and the 4.41x EV/EBITDA leaves substantial room for multiple expansion if investors gain confidence that mid-cycle earnings have reset higher.
Historical context is instructive: CF's PE ratio has ranged from roughly 3.8x in mid-2022 commodity boom conditions to over 25x in late 2023 earnings troughs, and the current 8.61x sits in the lower-middle portion of that band, well below the 10.0x-11.3x levels recorded through 2024-2025. The PS ratio of 1.77x, however, is dramatically below the 6.4x-10.1x readings across 2024-2026, though this reflects a data inconsistency in the historical series rather than a genuine re-rating. On balance, the valuation suggests the market is pricing in meaningful earnings normalization but not a return to trough conditions, leaving asymmetric upside if nitrogen prices prove stickier than feared.
PE
8.6x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 4x~14x
vs. Industry Avg
14.2x
Industry PE ~14.2x*
EV/EBITDA
4.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on earnings quality rather than balance-sheet stress. Debt-to-equity of 0.816 is moderate and the current ratio of 3.37 signals ample liquidity, but the earnings base is highly concentrated in a single commodity cycle: Q2 2026 EPS of $4.74 collapsed to $2.88 in Q3 as gross margin fell from 51.53% to 38.71%, showing how quickly the windfall can erode. Revenue is also concentrated in nitrogen products, with UAN ($639 million) and Ammonia ($534 million) dominating the $1.86 billion Q3 top line, leaving little diversification if fertilizer prices normalize faster than the $8.795 consensus EPS assumes. Quarterly interest expense of $168 million in Q3 (versus $50 million in Q2) is a reminder that leverage costs can spike and pressure net income.
Market and competitive risks are dominated by valuation compression tied to the unwinding geopolitical premium. The forward PE of 10.64x exceeding the trailing 8.61x signals the market already discounts falling earnings, and the 86% spread between the $105 low and $195.72 high analyst targets underscores how uncertain the normalized earnings power is. News of the Strait of Hormuz reopening in April 2026 and Iran truce hopes in May directly removes the supply disruption that drove the margin spike, while European and Asian competitors on costlier feedstock could regain share if US gas advantages narrow. With a beta of only 0.541, CF offers limited market correlation but is still exposed to sector rotation out of cyclical materials if global growth slows.
In a worst-case scenario, sustained nitrogen price normalization toward pre-shock levels would compress EBITDA margins from the current 54.84% back toward the 2025 baseline, driving EPS below the $7.86 low consensus estimate and forcing analysts toward the $105 bear target. A break below the $111-$115 support congestion zone would open a path toward the $100 psychological level, and a fuller re-rating toward the 52-week low of $75.42 would represent roughly a 37% decline from the current $119.39. Given the 25.75% max drawdown already endured from the $141.96 peak, investors should size positions for a realistic downside of -12% to the $105 analyst low and as much as -37% in a severe normalization scenario.
FAQ
The most severe risk is earnings mean-reversion: Q3 2026 EPS already fell to $2.88 from $4.74 in Q2 as gross margin compressed 12.8 points from the 51.53% peak to 38.71%, and a full normalization of nitrogen prices toward pre-shock levels could push EPS below the $7.86 low consensus estimate. Second is the unwinding geopolitical premium — the Strait of Hormuz reopened in April 2026 and Iran truce hopes in May removed the supply disruption that stranded a third of global fertilizer supply, directly eroding CF's margin windfall. Third is financial and operational concentration: revenue is dominated by nitrogen products (UAN $639 million and Ammonia $534 million of the $1.86 billion Q3 top line), and quarterly interest expense spiked to $168 million in Q3 from $50 million in Q2, pressuring net income. Fourth is valuation and sentiment risk — the 86% spread between the $105 low and $195.72 high analyst targets quantifies deep uncertainty about mid-cycle earnings, and a break below the $111-$115 support zone could accelerate selling toward $100.
The 12-month outlook splits into three scenarios. The base case (55% probability, $119.39-$128.79) assumes nitrogen prices normalize gradually, gross margins hold in the mid-to-high 30s, and EPS lands near the $8.795 consensus, tracking the $128.79 average analyst target. The bear case (25% probability, $75.42-$105.00) assumes a full unwind of the geopolitical premium compresses EBITDA margins from 54.84% and pushes EPS below $7.86, driving the stock toward the $105 analyst low and potentially the $75.42 52-week low. The bull case (20% probability, $141.96-$195.72) assumes sticky nitrogen prices, high-30s to low-40s gross margins, and multiple expansion toward the 12x-18x peer range, re-rating the stock toward the September high of $141.96 and ultimately the $195.72 high target. The base case is most likely, hinging on whether mid-cycle earnings hold near $8.795 — if they do, the 10.64x forward multiple is too cheap; if they roll back toward 2025 levels, the discount is deserved.
CF screens cheap on absolute and relative metrics: 8.61x trailing PE, 10.64x forward PE, 4.41x EV/EBITDA, 1.77x PS, and a 0.26 PEG ratio, all well below the 12x-18x range typical for agricultural chemical peers. The critical nuance is that the forward PE sits above the trailing PE — an inversion that signals the market expects the Hormuz-inflated earnings base to decline, with consensus forward EPS of $8.795 implying roughly $1.33 billion of net income versus the trailing run-rate. Against its own history, the 8.61x multiple sits in the lower-middle of a wide 3.8x-to-25x band and below the 10.0x-11.3x levels of 2024-2025, suggesting modest undervaluation relative to recent norms. The market is therefore pricing meaningful earnings normalization but not a return to trough conditions, which leaves room for upside if nitrogen prices prove stickier than feared — but the discount is largely deserved given genuine cyclical earnings risk.
From a risk/reward standpoint CF is a balanced, not compelling, proposition at $119.39. The stock trades at 8.61x trailing and 10.64x forward earnings — a 30-50% discount to the 12x-18x agricultural chemical peer range — yet the average analyst target of $128.79 implies only 7.9% upside, and the 13-Hold/6-Buy/3-Sell consensus (recommendation mean 2.82) confirms the Street sees it as fairly valued after a 46.58% one-year run. The biggest downside risk is a full unwind of the Hormuz-driven nitrogen premium, which could pull the stock toward the $105 analyst low (-12%) or, in a severe normalization, the $75.42 52-week low (-37%). The upside case is supported by $2.081 billion of TTM free cash flow, a 2.6% dividend, and a ~10% share-count reduction that protect per-share value even as margins cool. It is a reasonable buy for patient value and income investors who can tolerate cyclicality and are comfortable accumulating nearer the $105-$111 support zone, but at current levels the risk/reward is roughly symmetric rather than asymmetric.
CF is better suited to a medium-to-long-term holding period of at least 12-18 months than to short-term trading. Its beta of 0.541 means it is roughly 46% less volatile than the market, which limits the sharp swings momentum traders seek, and its 4.33% one-month and 4.41% three-month gains show the powerful 2026 rally has flattened into sideways churn since September. The 2.6% dividend yield (covered by a conservative 22.4% payout ratio) and the ongoing buyback that cut diluted shares from 168.8 million to 151.6 million reward patient holders with total return rather than quick capital appreciation. Earnings visibility is limited by commodity nitrogen pricing, so the thesis needs time to resolve — either the $8.795 consensus EPS proves durable and the multiple re-rates, or normalization plays out and the stock drifts toward the $105-$111 support zone. A concrete minimum holding period of 12-18 months, ideally accumulating on pullbacks toward $105-$111, aligns with the cyclical earnings cycle and the base-case 55% probability path.